Cargando…

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

BACKGROUND: Cytomegalovirus (CMV) infections that are refractory or resistant (RR) to available antivirals ([val]ganciclovir, foscarnet, cidofovir) are associated with higher mortality in transplant patients. Maribavir is active against RR CMV strains. METHODS: Hematopoietic-cell or solid-organ tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papanicolaou, Genovefa A, Silveira, Fernanda P, Langston, Amelia A, Pereira, Marcus R, Avery, Robin K, Uknis, Marc, Wijatyk, Anna, Wu, Jingyang, Boeckh, Michael, Marty, Francisco M, Villano, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451997/ https://www.ncbi.nlm.nih.gov/pubmed/30329038 http://dx.doi.org/10.1093/cid/ciy706

Ejemplares similares

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial( )
por: Avery, Robin K, et al.
Publicado: (2021)

Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus
por: Gandhi, Ronak G, et al.
Publicado: (2022)

Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient
por: Schubert, Axel, et al.
Publicado: (2013)

21. Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results
por: Pereira, Marcus, et al.
Publicado: (2021)

Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection
por: Chou, Sunwen, et al.
Publicado: (2020)

Maribavir for Cytomegalovirus Treatment in the Real World—Not a Silver Bullet
por: Fung, Monica, et al.
Publicado: (2022)

595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study
por: Han, Gyuri, et al.
Publicado: (2021)

Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus
por: Sun, Kefeng, et al.
Publicado: (2023)

1104. Risk Factors and Outcomes of Refractory and/or Resistant Cytomegalovirus (CMV) Infection after Allogeneic Hematopoietic Stem Cell Transplantation
por: Karantoni, Eleni, et al.
Publicado: (2020)

The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein
por: Shannon-Lowe, Claire D, et al.
Publicado: (2010)

Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients
por: Waghmare, Alpana, et al.
Publicado: (2020)

BK Polyoma Virus Nephropathy in Hematopoietic Cell Transplant Recipients with Renal Dysfunction
por: Lee, Yeon Joo, et al.
Publicado: (2017)

Correction to: Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
Publicado: (2023)

Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study
por: Ilic, Katarina, et al.
Publicado: (2020)

Cutaneous Legionella infections in allogeneic hematopoietic cell transplantation recipients
por: Vaidya, Toral, et al.
Publicado: (2020)

Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant
por: Prockop, Susan E., et al.
Publicado: (2023)

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
por: Marty, Francisco M., et al.
Publicado: (2018)

1761. A Single-Center Experience with Cidofovir for the Treatment of Double-Stranded (ds) DNA Viruses in Hematopoietic Cell Transplant (HCT) Recipients
por: Stern, Anat, et al.
Publicado: (2019)

Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
por: Dioverti, Veronica, et al.
Publicado: (2022)

91. Differential Impact of Cytomegalovirus (CMV) Donor (D) Serostatus on Rates and Kinetics of CMV Viremia among CMV Seropositive Recipients (R+) of Ex vivo T-cell Depleted (TCD) and Unmodified (CONV) Hematopoietic Cell Transplants (HCT)
por: Stern, Anat, et al.
Publicado: (2019)

Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with Cytomegalovirus
por: Houldcroft, Charlotte J., et al.
Publicado: (2016)

S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
por: Duarte, Rafael F, et al.
Publicado: (2023)

1563. Relationship of Cumulative Viral Burden of Adenovirus with Mortality in Allogeneic Hematopoietic Cell Transplant Recipients with Early Adenovirus Viremia
por: Lee, Yeon Joo, et al.
Publicado: (2018)

452 Pseudo-Outbreak of Fulminant Toxoplasmosis in Hematopoietic Stem Cell Transplant [HSCT] Recipients
por: Isa, Flonza, et al.
Publicado: (2014)

Cytomegalovirus –The Quest for an Effective Vaccine in Transplant Recipients Continues
por: Boeckh, Michael, et al.
Publicado: (2015)

Real-World Experience of Voriconazole Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Single-Center Study
por: Chan, Shuk-Ying, et al.
Publicado: (2017)

Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study
por: Song, Ivy, et al.
Publicado: (2022)

The challenge of respiratory virus infections in hematopoietic cell transplant recipients
por: Boeckh, Michael
Publicado: (2008)

Synthesis of New Imidazopyridine Nucleoside Derivatives Designed as Maribavir Analogues
por: Papadakis, Georgios, et al.
Publicado: (2020)

Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
por: Gill, Rachel B, et al.
Publicado: (2009)

Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection
por: Faure Bardon, Valentine, et al.
Publicado: (2020)

Frequently Asked Questions about Mpox (Formerly Monkeypox Disease) for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Recipients from the American Society for Transplantation and Cellular Therapy
por: Ford, Emily S., et al.
Publicado: (2023)

923. Respiratory Syncytial and Parainfluenza Virus Infection Increase the Risk of Cytomegalovirus Reactivation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Xie, Hu, et al.
Publicado: (2021)

A multicenter, longitudinal, interventional, double blind randomized clinical trial in hematopoietic cell transplant recipients residing in remote areas: Lessons learned from the late cytomegalovirus prevention trial
por: Kimball, Louise E., et al.
Publicado: (2016)

2735. Treatment patterns and clinical outcomes of acyclovir resistant and refractory human herpes simplex virus infection after allogeneic hematopoietic cell transplantation
por: Lee, Yeon Joo, et al.
Publicado: (2023)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

Effects of Maribavir on P‐Glycoprotein and CYP2D6 in Healthy Volunteers
por: Song, Ivy H., et al.
Publicado: (2019)

1855. Understanding Cytomegalovirus (CMV) Symptom Management, Quality of Life, and Care Coordination in Transplant Recipients Through Patient and Care Partner (CP) Experiences
por: Singh, Deepshikha, et al.
Publicado: (2023)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Infection in the Hematopoietic Stem Cell Transplant Recipient
por: Marty, Francisco M., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_dsvj4re5p6vm3m76l600vjjv3e